This study examined the technical feasibility, safety, and effectiveness of using a Pipeline Embolization Device (PED) to treat intracranial aneurysms located in parent vessels less than 2 mm wide. The research involved 71 patients with these specific conditions, drawn from multiple medical centers. The team tracked outcomes for a median of 9 months, looking at how well the device blocked blood flow and checking for serious safety issues like stroke or bleeding.
The results showed that complete aneurysm closure was achieved in 52% of patients at one year. Over the long term, defined as more than 12 months of follow-up, the closure rate increased to 80%. However, the study also identified significant safety concerns. Ischemic events, which include strokes or reduced blood flow, occurred in 16.9% of the patients. Additionally, 4.2% experienced hemorrhagic events, and 12.7% developed asymptomatic narrowing in the stent.
Several specific associations were found that readers should note carefully. Longer devices were linked to a higher likelihood of delayed aneurysm closure and a greater risk of ischemic complications. Pre-existing narrowing in the parent vessel was strongly associated with the development of asymptomatic in-stent stenosis. Because this was a retrospective study with a small sample size and no direct comparison group, the observed links do not prove cause and effect. Readers should understand that this early evidence is limited and does not yet confirm that the device is safe or effective for this specific use.